, Volume 7, Supplement 5, pp S507–S512 | Cite as

Aminopenicillins: Concluding remarks

  • T. Bergan
Clinical Evaluation


This symposium has focused on the bacteriological, pharmacokinetic, therapeutic, and adverse effects of the aminopenicillins. The compounds which are currently being assessed are primarily amoxycillin, ampicillin, bacampicillin, pivampicillin, and talampicillin. The three last mentioned are prodrugs which upon gastrointestinal absorption are rapidly split to yield circulating ampicillin. Pharmacokinetics and side-effects are reasons why one may narrow the selection of most suitable compounds within this group down to three. Ampicillin and amoxycillin are primary choices for parenteral dosage, and amoxycillin and bacampicillin the most suitable for oral therapy.


Adverse Effect Internal Medicine Infectious Disease General Practice Ampicillin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Dieses Symposium hat die bakteriologischen, pharmakokinetischen und therapeutischen Seiten, sowie die Nebeneffekte der Aminopenicilline hervorgehoben. Die wichtigsten Substanzen, die gegenwärtig verglichen werden müssen, sind besonders Amoxycillin, Ampicillin, Bacampicillin, Pivampicillin und Talampicillin. Die drei letzteren sind Vormedikamente, die während der Absorption im Darm unter Freigabe von gewöhnlichem Ampicillin hydrolysiert werden. Pharmakokinetische Eigenschaften sowie die Rate an Nebenwirkungen sind die Hauptgründe, weswegen die Auswahl der Aminopenicilline gegenwärtig auf einige wenige beschränkt werden muß. Ampicillin und Amoxycillin sind für parenterale Gabe die wichtigste Alternative, während für orale Gabe Amoxycillin und Bacampicillin als Vorzugspräparate in Frage kommen.


  1. 1.
    Davies, B., Maesen, F.: Serum and sputum antibiotic levels after ampicillin, amoxycillin and bacampicillin in chronic bronchitis patients. Infection 7 Suppl. 1 (1979).Google Scholar
  2. 2.
    Ekström, B., Jalar, L.-P., Magni, L.: Comparative in vivo activity of bacampicillin and amoxycillin. Infection 7 Suppl. 1 (1979).Google Scholar
  3. 3.
    Mattie, H., van der Voet, G. B. Influence of aminopenicillins on bacterial growth kinetics in vitro in comparison with the antibacterial effect in vivo. Infection 7 Suppl. 1 (1979) 434–437.Google Scholar
  4. 4.
    Ritzerfeld, W. Efficacy of bacampicillin and ampicillin in experimental pyelonephritis in the rat. Infection 7 Suppl. 1 (1979) 443–447.Google Scholar
  5. 5.
    Bergogne-Berezin, E., Berthelot, G., Kafe, H., Morel, C. Penetration of bacampicillin into human bronchial secretions. Infection 7 Suppl. 1 (1979) 463–464.Google Scholar
  6. 6.
    Hällström, O., Keyriläinen, O., Markkula, H. Ampicillin concentration in normal and pathological lung tissues after oral administration of bacampicillin. Infection 7 Suppl. 1 (1979) 469–471.Google Scholar
  7. 7.
    Heimdahl, A., Nord, C. E., Weilander, K. Effect of bacampicillin on human mouth, throat and colon flora. Infection 7 Suppl. 1 (1979) 446–451.Google Scholar
  8. 8.
    Kallings, L. O., Eriksson, G., Hoffner, S. Penetration into urethra and cervix secretions after oral administration of bacampicillin. Infection 7 Suppl. 1 (1979) 478–481.Google Scholar
  9. 9.
    Mattie, H., Meenhorst, P. Clinical pharmacological evaluation of aminopenicillin. Infection 7 Suppl. 1 (1979) 456–458.Google Scholar
  10. 10.
    Reeves, D. S., Bullock, D. W. Aminopenicillins: Development and comparative properties. Infection 7 Suppl. 1 (1979) 425–433.Google Scholar
  11. 11.
    Sjövall, J. Dose dependence in human absorption of aminopenicillins. Infection 7 Suppl. 1 (1979) 458–462.Google Scholar
  12. 12.
    Sorri, M., Jokinen, K., Peltomäki, E. A pharmacokinetic study with bacampicillin in patients with chronic maxillary sinusitis. Infection 7 Suppl. 1 (1979) 475–477.Google Scholar
  13. 13.
    Virtanen, S., Lahikainen, E. A. Ampicillin concentrations in middle ear effusions in acute otitis media after administration of bacampicillin. Infection 7 Suppl. 1 (1979) 472–474.Google Scholar
  14. 14.
    Svanborg-Edén, C., Sandberg, T., Stenqvist, K., Ahlstedt, S. Effects of subinhibitory amounts of ampicillin, amoxycillin and mecillinam on the adhesion ofEscherichia coli bacteria to human urinary tract epithelial cells. A preliminary study. Infection 7 Suppl. 1 (1979) 452–454.Google Scholar
  15. 15.
    Helm, E. B., Munk, I., Shah, P. M., Stille, W. Elimination of bacteria during antibacterial chemotherapy in urine; a neglected parameter of chemotherapy. Infection 7 Suppl. 1 (1979) 492–494.Google Scholar
  16. 16.
    Koldenstam, Å., Olsson, S., Berglund, L. A double blind comparison of the clinical tolerance of bacampicillin and pivampicillin. Infection 7 Suppl. 1 (1979) 495–498.Google Scholar
  17. 17.
    Maesen, F., Davies, B. Acute exacerbation of chronic bronchitis: a comparison of ampicillin, ampicillin esters (bacampicillin and pivampicillin) and amoxycillin. Infection 7 Suppl. 1 (1979) 483–486.Google Scholar
  18. 18.
    Müller-Ehrenberg, Müller, G. Bacampicillin and ampicillin in urinary tract infections: A double-blind comparison of efficacy and tolerance. Infection 7 Suppl. 1 (1979) 489–491.Google Scholar
  19. 19.
    Wallin, J., Bengtsson, S., Eriksson, G., Kallings, L. O., Sandström, E., Wallmark, G. A dose response study with bacampicillin in uncomplicated gonorrhoea. Infection 7 Suppl. 1 (1979) 487–488.Google Scholar
  20. 20.
    Ahlstedt, S., Kristofferson, A. Experimental evidence for a decreased incidence of penicillin allergy by use of pure penicillins. Infection 7 Suppl. 1 (1979) 499–502.Google Scholar
  21. 21.
    Nordbring, F. Review of side-effects of aminopenicillins. Infection 7 Suppl. 1 (1979) 503–506.Google Scholar
  22. 22.
    Birnbaum, J., Stapley, E. O., Miller, A. K., Wallick, H., Hendlin, D., Woodruff, H. B. Cefoxitin, a semi-synthetic cephamycin: a microbiological overview. J. Antimicrob. Chemother. 4 Suppl. B (1978) 15–32.Google Scholar
  23. 23.
    Ho, P. P. K., Towner, R. D. Biochemical and microbiological studies on 6-substituted penicillins. J. Antibiot. 25 (1972) 627–628.Google Scholar
  24. 24.
    Bergan, T. Penicillins. Antibiot. Chemother. 25 (1978) 1–122.Google Scholar
  25. 25.
    Sjövall, J., Magni, L., Bergan, T. Pharmacokinetics of bacampicillin compared with those of ampicillin, pivampicillin, and amoxycillin. Antimicrob. Ag. Chemother. 13 (1978) 90–96.Google Scholar
  26. 26.
    Rozencweig, M., Staquet, M., Klastersky, J. Antibacterial activity and pharmacokinetics of bacampicillin and ampicillin. Clin. Pharmacol. Ther. 19 (1976) 592–597.Google Scholar
  27. 27.
    Bergan, T. Pharmacokinetic comparison of oral bacampicillin and parenteral ampicillin. Antimicrob. Ag. Chemother. 13 (1978) 971–974.Google Scholar
  28. 28.
    Spyker, D. A., Rugloski, R. J., Vann, R. L., O'Brien, W. M. Pharmacokinetics of amoxycillin: Dose dependence after intravenous, oral and intramuscular administration. Antimicrob. Ag. Chemother. 11 (1977) 132–141.Google Scholar
  29. 29.
    Zarowny, D., Ogilvie, R., Tamblyn, D., Macleaod, C., Reudy, J. Pharmacokinetics of amoxycillin. Clin. Pharmacol. Ther. 16 (1974) 1045–1051.Google Scholar
  30. 30.
    Loo, J. C. K., Foltz, E. L., Wallick, H., Kwan, K. C. Pharmacokinetics of pivampicillin and ampicillin in man. Clin. Pharmacol. Ther. 16 (1974) 35–43.Google Scholar
  31. 31.
    Bergan, T., Digranes, A., Schreiner, A. Absorption, distribution and elimination of cefazolin in patients with normal renal function. Chemotherapy 24 (1978) 277–282.Google Scholar
  32. 32.
    Bergan, T. Kinetics of tissue penetration. Are high plasma peak concentrations or sustained levels preferable for effective antibiotic therapy? Scand. J. Infect. Dis. Suppl. 14 (1978) 36–46.Google Scholar
  33. 33.
    May, J. R., Ingold, A. Amoxycillin in the treatment of infections of the lower respiratory tract. J. Infect. Dis. 129 Suppl. (1974) 189–193.Google Scholar
  34. 34.
    Rauws, A. G., van Klingeren, B. Estimation of antibiotic levels in interstitial fluid from whole tissue levels. Scand. J. Infect. Dis. Suppl. 14 (1978) 186–188.Google Scholar
  35. 35.
    Ericsson, G., Magni, L., Wessman, J. Pharmacological considerations of the treatment of gonorrhoea with oral ampicillin. In:Hejzlar, M., Semonský, M., Másak, S. (eds.): Advances in antimicrobial and antineoplastic Chemotherapy, Vol. 1. Urban & Schwarzenberg, München, 1972, pp. 1401–1403.Google Scholar
  36. 36.
    Tune, B. M. Relationship between the transport and toxicity of cephalosporins in the kidney. J. Infect. Dis. 132 (1975) 189–194.Google Scholar
  37. 37.
    Simon, C., Malerczyk, V., Klaus, M. Absorption of bacampicillin and ampicillin and penetration into body fluids (skin blister fluid, saliva, tears) in healthy volunteers. Scand. J. Infect. Dis. Suppl. 14 (1978) 228–232.Google Scholar
  38. 38.
    Sande, M. A., Sherertz, R. J., Zak, O., Dacey, R. G., Bodine, J. A., Straustaugh, L. J. Factors influencing the penetration of antimicrobial agents into the cerebrospinal fluid of experimental animals. Scand. J. Infect. Dis. Suppl. 14 (1978) 160–163.Google Scholar
  39. 39.
    Comber, K. R., Boon, R. J., Sutherland, R. Comparative effects of amoxycillin and ampicillin on the morphology ofEscherichia coli in vivo and correlation with activity. Antimicrob. Ag. Chemother. 12 (1977) 736–744.Google Scholar
  40. 40.
    Hunter, P. A., Rolinson, G. N., Witting, D. A. Comparative activity of amoxycillin and ampicillin in an experimental bacterial infection in mice. Antimicrob. Ag. Chemother. 4 (1973) 285–293.Google Scholar
  41. 41.
    Rolinson, G. N., MacDonald, A. C., Wilson, D. A. Bactericidal action of β-lactam antibiotics onEscherichia coli with particular reference to ampicillin and amoxycillin. J. Antimicr. Chemother. 3 (1977) 541–553.Google Scholar
  42. 42.
    Garrett, E. R. Kinetics of antimicrobial action. Scand. J. Infect. Dis. Suppl. 14 (1978) 54–85.Google Scholar
  43. 43.
    Bergeron, M. G. A review of models for the therapy of experimental infections. Scand. J. Infect. Dis. Suppl. 14 (1978) 189–206.Google Scholar
  44. 44.
    Bergan, T., Versland, I. The mini-pig as a model for penetration of penicillins. Scand. J. Infect. Dis. Suppl. 14 (1978) 135–142.Google Scholar
  45. 45.
    Frøholm, L. O., Sletten, K. Purification and N-terminal sequence of a fimbrial protein fromMoraxella nonliquefaciens. FEBS Letters 73 (1977) 29–32.Google Scholar
  46. 46.
    Spratt, B. G. Distinct penicillin binding proteins involved in the division, elongation, and shape ofEscherichia coli K12. Proc. Nat. Acad. Sci. USA 72 (1975) 2999–3003.Google Scholar
  47. 47.
    Neringer, R., Strömberg, A.: Comparative study of amoxicillin and pivampicillin with regard to side-effects. Manuscript in preperation (1978).Google Scholar
  48. 48.
    Danø, P., Hansen, P. F. Antibiotic treatment with pivampicillin chloride in respiratory and urinary tract infections. Chemotherapy 18 (1973) 63–71.Google Scholar
  49. 49.
    Hey, H., Medalen, T. J., Mølstad, O. M., Stokholm, K. A clinical evaluation of the tolerance to pivampicillin tablets. Infection 5 (1977) 22–25.Google Scholar

Copyright information

© Verlagsgesellschaft Otto Spatz 1979

Authors and Affiliations

  • T. Bergan
    • 1
  1. 1.Department of MicrobiologyInstitute of PharmacyOslo 3Norway

Personalised recommendations